|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-9-2
|
|
pubmed:abstractText |
ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Neuregulin-1,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1535-6108
|
|
pubmed:author |
pubmed-author:AgusDavid BDB,
pubmed-author:AkitaRobert WRW,
pubmed-author:EvansDouglas PDP,
pubmed-author:FoxWilliam DWD,
pubmed-author:HigginsBrianB,
pubmed-author:LewisGail DGD,
pubmed-author:LofgrenJulie AJA,
pubmed-author:MaieseKristaK,
pubmed-author:PisacanePaul IPI,
pubmed-author:ScherHoward IHI,
pubmed-author:SliwkowskiMark XMX,
pubmed-author:TindellCharlesC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-37
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12204533-Androgens,
pubmed-meshheading:12204533-Animals,
pubmed-meshheading:12204533-Antibodies, Monoclonal,
pubmed-meshheading:12204533-Antineoplastic Agents,
pubmed-meshheading:12204533-Breast Neoplasms,
pubmed-meshheading:12204533-Cell Division,
pubmed-meshheading:12204533-Female,
pubmed-meshheading:12204533-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12204533-Humans,
pubmed-meshheading:12204533-Ligands,
pubmed-meshheading:12204533-Male,
pubmed-meshheading:12204533-Mice,
pubmed-meshheading:12204533-Neoplasm Transplantation,
pubmed-meshheading:12204533-Neuregulin-1,
pubmed-meshheading:12204533-Prostatic Neoplasms,
pubmed-meshheading:12204533-Protein Binding,
pubmed-meshheading:12204533-RNA, Messenger,
pubmed-meshheading:12204533-Receptor, erbB-2,
pubmed-meshheading:12204533-Receptor, erbB-3,
pubmed-meshheading:12204533-Signal Transduction,
pubmed-meshheading:12204533-Time Factors,
pubmed-meshheading:12204533-Transplantation, Heterologous,
pubmed-meshheading:12204533-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
|
|
pubmed:affiliation |
Cedars-Sinai Prostate Cancer Center, Los Angeles, California 90048, USA.
|
|
pubmed:publicationType |
Journal Article,
Comment,
Research Support, Non-U.S. Gov't
|
